3 AI Stocks Set to Soar in 2023
Eric Fry just released the names of 3 AI-driven stocks he believes every investor should own, even in these crazy markets — one stock is up over 100% since the beginning of 2023.

Click here to learn their names – FOR FREE.
Richard A.  Gonzalez net worth and biography

Richard Gonzalez Biography and Net Worth

CEO of AbbVie
Richard A. Gonzalez is Chairman of the Board and Chief Executive Officer of AbbVie, a global biopharmaceutical company that employs approximately 48,000 people worldwide and markets medicines in more than 175 countries. 

Prior to AbbVie’s separation from Abbott in January 2013, Mr. Gonzalez was a 30-year Abbott veteran. He served as President and Chief Operating Officer of Abbott before briefly retiring in 2007. He also held various senior leadership positions in Abbott’s medical products businesses, including President and Chief Operating Officer of the Medical Products Group; Senior Vice President and President of the former Hospital Products Division; Vice President and President of the Health Systems Division; and Divisional Vice President and General Manager for Diagnostics Operations in the United States and Canada. 

Mr. Gonzalez has been a long-standing leader in the greater Chicago community where he is a member of the Commercial Club of Chicago and represents AbbVie on their Civic Committee. He is also a member of the Business Roundtable, which is the only national organization representing exclusively CEOs of America’s leading companies.

What is Richard A. Gonzalez's net worth?

The estimated net worth of Richard A. Gonzalez is at least $95.93 million as of July 31st, 2023. Mr. Gonzalez owns 625,294 shares of AbbVie stock worth more than $95,926,353 as of September 21st. This net worth evaluation does not reflect any other investments that Mr. Gonzalez may own. Additionally, Mr. Gonzalez receives a salary of $6,950,000.00 as CEO at AbbVie. Learn More about Richard A. Gonzalez's net worth.

How old is Richard A. Gonzalez?

Mr. Gonzalez is currently 69 years old. There are 7 older executives and no younger executives at AbbVie. Learn More on Richard A. Gonzalez's age.

What is Richard A. Gonzalez's salary?

As the CEO of AbbVie Inc., Mr. Gonzalez earns $6,950,000.00 per year. Learn More on Richard A. Gonzalez's salary.

How do I contact Richard A. Gonzalez?

The corporate mailing address for Mr. Gonzalez and other AbbVie executives is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. AbbVie can also be reached via phone at (847) 932-7900. Learn More on Richard A. Gonzalez's contact information.

Has Richard A. Gonzalez been buying or selling shares of AbbVie?

During the past quarter, Richard A. Gonzalez has sold $2,759,275.00 of AbbVie stock. Most recently, Richard A. Gonzalez sold 18,500 shares of the business's stock in a transaction on Monday, July 31st. The shares were sold at an average price of $149.15, for a transaction totalling $2,759,275.00. Following the completion of the sale, the chief executive officer now directly owns 625,294 shares of the company's stock, valued at $93,262,600.10. Learn More on Richard A. Gonzalez's trading history.

Who are AbbVie's active insiders?

AbbVie's insider roster includes Carlos Alban (Vice Chairman), Roxanne Austin (Director), Nicholas Donoghoe (SVP), Brian Durkin (VP), Richard Gonzalez (CEO), Henry Gosebruch (EVP), Robert Michael (Vice Chairman), Scott Reents (Sr. VP & CFO ), Scott Reents (CFO), Timothy Richmond (EVP), Azita Saleki-Gerhardt (EVP), Laura Schumacher (Vice Chairman), Michael Severino (Vice Chairman), Perry Siatis (EVP), Elaine Sorg (SVP), Jeffrey Stewart (EVP), and Carrie Strom (SVP). Learn More on AbbVie's active insiders.

Are insiders buying or selling shares of AbbVie?

During the last year, insiders at the sold shares 13 times. They sold a total of 252,767 shares worth more than $39,139,460.99. The most recent insider tranaction occured on July, 31st when CEO Richard A Gonzalez sold 18,500 shares worth more than $2,759,275.00. Insiders at AbbVie own 0.3% of the company. Learn More about insider trades at AbbVie.

Information on this page was last updated on 7/31/2023.

Richard A. Gonzalez Insider Trading History at AbbVie

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/31/2023Sell18,500$149.15$2,759,275.00625,294View SEC Filing Icon  
12/9/2021Sell174,100$123.23$21,454,343.00View SEC Filing Icon  
3/1/2021Sell170,113$108.61$18,475,972.93450,981View SEC Filing Icon  
12/11/2018Sell16,850$88.75$1,495,437.50286,203View SEC Filing Icon  
2/28/2018Sell8,280$117.88$976,046.40321,292View SEC Filing Icon  
11/21/2017Sell218,193$94.01$20,512,323.93492,030View SEC Filing Icon  
8/7/2017Sell193,131$71.00$13,712,301.00469,623View SEC Filing Icon  
8/4/2017Sell87,899$71.02$6,242,586.98342,353View SEC Filing Icon  
8/3/2017Sell65,861$71.00$4,676,131.00342,353View SEC Filing Icon  
5/19/2017Sell71,235$65.49$4,665,180.15349,462View SEC Filing Icon  
3/8/2017Sell72,016$64.25$4,627,028.00369,113View SEC Filing Icon  
6/2/2016Sell285,953$63.82$18,249,520.46624,374View SEC Filing Icon  
5/11/2016Sell39,000$63.80$2,488,200.00338,421View SEC Filing Icon  
4/28/2015Sell102,964$64.67$6,658,681.88View SEC Filing Icon  
See Full Table

Richard A. Gonzalez Buying and Selling Activity at AbbVie

This chart shows Richard A Gonzalez's buying and selling at AbbVie by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

AbbVie Company Overview

AbbVie logo
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; Genentech, Inc.; and California Institute for Biomedical Research (Calibr). The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Read More

Today's Range

Now: $152.80
Low: $152.54
High: $153.90

50 Day Range

MA: $147.54
Low: $133.56
High: $153.93

2 Week Range

Now: $152.80
Low: $130.96
High: $168.11


239,124 shs

Average Volume

5,604,206 shs

Market Capitalization

$269.70 billion

P/E Ratio


Dividend Yield



Better Than Oil Stocks?
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment.